XML 27 R13.htm IDEA: XBRL DOCUMENT
v3.19.2

STOCK-BASED COMPENSATION | 12 Months Ended
--- | ---
Jun. 30, 2019
STOCK-BASED COMPENSATION |
STOCK-BASED COMPENSATION | 7. STOCK‑BASED COMPENSATION In November 2015, shareholders of the Company approved the 2015 Omnibus Long‑Term Incentive Plan (“2015 LTIP”). Under the 2015 LTIP, 2,500,000 shares of common stock have been authorized for future grants to officers, directors, key employees and other persons. The 2015 LTIP provides for the grant of stock options, unrestricted stock, restricted stock, dividend equivalent rights, SSARs and cash awards. Any of these awards may, but need not, be made as performance incentives. Stock options granted under the 2015 LTIP may be non‑qualified stock options or incentive stock options. The Company recognized stock‑based compensation expense as follows:
|  | Fiscal Year Ended June 30,
|  | 2019 |  | 2018 |  | 2017
|  |  | (Amounts in thousands)
Stock options |  | $ | 221 |  | $ | 318 |  | $ | 393
Stock appreciation rights |  |  | 2,025 |  |  | 1,988 |  |  | 1,851
Restricted stock |  |  | 3,336 |  |  | 4,487 |  |  | 3,840
Performance stock |  |  | 1,035 |  |  | 1,486 |  |  | 3,899
Total stock-based compensation expense |  | $ | 6,617 |  | $ | 8,279 |  | $ | 9,983
Stock‑based compensation expense is included within General and administrative expense on the consolidated statements of operations and comprehensive income (loss). Stock Options and Stock Appreciation Rights Stock option and SSARs awards are granted with an exercise price equal to the closing market price of the Company’s stock at the date of grant. Stock option and SSARs awards granted to officers, key employees and other persons vest based on one to three years of continuous service. Stock option and SSARs awards have 10 year contractual terms. To determine stock‑based compensation expense for stock options and SSARs, the fair value of each stock option and SSAR is estimated on the date of grant using the Black‑Scholes‑Merton (“Black‑Scholes”) option pricing model for all periods presented. The Black‑Scholes model requires key assumptions in order to determine fair value. Those key assumptions during the fiscal year 2019, 2018 and 2017 grants are noted in the following table:
|  | Stock Options |  | SSARs |
|  | 2019 |  | 2018 |  | 2017 |  | 2019 |  | 2018 |  | 2017 |
Weighted-average expected volatility |  | 36.5 | % | 42.2 | % | 41.7 | % | 37.6 | % | 42.4 | % | 41.1 | %
Weighted-average expected life in years |  | 4.5 |  | 5.5 |  | 5.5 |  | 5.2 |  | 5.4 |  | 5.8 |
Weighted-average dividend yield |  | 1.13 | % | 1.10 | % | 1.11 | % | 1.13 | % | 1.10 | % | 1.11 | %
Weighted-average risk free interest rate |  | 2.7 | % | 1.8 | % | 1.2 | % | 2.7 | % | 1.8 | % | 1.3 | %
The Company’s expected volatility is based on the historical volatility of the Company’s stock over the expected option term. The Company’s expected option term is determined by historical exercise patterns along with other known employee or company information at the time of grant. The risk free interest rate is based on the zero‑coupon U.S. Treasury bond at the time of grant with a term approximate to the expected option term. Stock Options A summary of stock option activity for the fiscal year ended June 30, 2019, is presented below.
|  |  |  |  |  |  | Weighted- |  |  |
|  |  |  | Weighted- |  | Average |  |  |
|  |  |  | Average |  | Remaining |  | Aggregate
|  | Number of |  | Exercise |  | Contractual |  | Intrinsic Value
|  | Shares |  | Price |  | Life (Years) |  | (in thousands)
Outstanding at July 1, 2018 |  | 66,227 |  | $ | 69.35 |  |  |  |  |
Granted |  | 6,430 |  | $ | 77.73 |  |  |  |  |
Exercised |  | (27,930) |  | $ | 68.19 |  |  |  |  |
Expired |  | (2,429) |  | $ | 82.29 |  |  |  |  |
Outstanding at June 30, 2019 |  | 42,298 |  | $ | 70.65 |  | 5.9 |  | $ | 1,334
Exercisable at June 30, 2019 |  | 32,125 |  | $ | 67.30 |  | 5.2 |  | $ | 1,130
The weighted‑average grant date fair value of options granted during the fiscal years ended June 30, 2019, 2018 and 2017, was $24.12, $27.12 and $29.54, respectively. The total intrinsic value of options exercised during the fiscal years ended June 30, 2019, 2018 and 2017, were $0.7 million, $1.4 million, and $0.5 million, respectively. As of June 30, 2019, there was approximately $0.1 million of total unrecognized stock‑based compensation expense related to non‑vested stock options, which is expected to be recognized over a weighted‑average period of 1.7 years. SSARs A summary of SSARs activity for the fiscal year ended June 30, 2019, is presented below.
|  |  |  |  |  |  | Weighted- |  |  |
|  |  |  | Weighted- |  | Average |  |  |
|  |  |  | Average |  | Remaining |  | Aggregate
|  | Number of |  | Exercise |  | Contractual |  | Intrinsic Value
|  | Shares |  | Price |  | Life (Years) |  | (in thousands)
Outstanding at July 1, 2018 |  | 252,886 |  | $ | 75.60 |  |  |  |  |
Granted |  | 72,860 |  | $ | 78.06 |  |  |  |  |
Exercised |  | (144,360) |  | $ | 71.99 |  |  |  |  |
Expired |  | (5,787) |  | $ | 87.42 |  |  |  |  |
Outstanding at June 30, 2019 |  | 175,599 |  | $ | 79.20 |  | 8.0 |  | $ | 4,090
Exercisable at June 30, 2019 |  | 53,886 |  | $ | 73.46 |  | 6.8 |  | $ | 1,565
The weighted‑average grant date fair value of SSARs granted during the fiscal years ended June 30, 2019, 2018 and 2017 was $26.37, $29.17 and $29.76, respectively. The total intrinsic value of SSARs exercised during the fiscal years ended June 30, 2019, 2018 and 2017, was $2.8 million, $6.4 million, and $0.2 million, respectively. As of June 30, 2019, there was approximately $1.9 million of total unrecognized stock‑based compensation expense related to non‑vested SSARs, which is expected to be recognized over a weighted‑average period of 1.7 years. Other Stock‑based Compensation Performance Shares During fiscal 2019, officers and certain employees were granted shares of restricted common stock that can be earned only upon the Company’s achievement of certain pre‑defined performance measures. Specifically, for performance shares granted in fiscal 2019, one‑half of the shares awarded may vest upon the Company’s achievement of annual growth in Net Gold Equivalent Ounces (“Net GEOs”) (“GEO Shares”). The second one‑half of performance shares granted in fiscal 2019 may vest based on the Company’s total shareholder return (“TSR”) compared to the TSRs of other members of the Market Vectors Gold Miners ETF (GDX) (“TSR Shares”). GEO Shares and TSR Shares may vest by linear interpolation in a range between zero shares if neither threshold Net GEO and TSR metric is met; to 100% of GEO Shares and TSR Shares awarded if both target Net GEO and TSR metrics are met; to 200% of the Net GEO and TSR shares awarded if both the maximum Net GEO and TSR metrics are met. The GEO Shares will expire in five years from the date of grant if the performance measure is not met, while the TSR Shares will expire in three years from the date of grant if the TSR market condition and three year service condition are not met. The Company measures the fair value of the GEO Shares based upon the market price of our common stock as of the date of grant. In accordance with ASC 718, the measurement date for the GEO Shares will be determined at such time that the performance goals are attained or that it is probable they will be attained. At such time that it is probable that a performance condition will be achieved, compensation expense will be measured by the number of shares that will ultimately be earned based on the grant date market price of our common stock. For shares that were previously estimated to be probable of vesting and are no longer deemed to be probable of vesting, compensation expense is reversed during the period in which it is determined they are no longer probable of vesting. Interim recognition of compensation expense will be made at such time as management can reasonably estimate the number of shares that will be earned. In accordance with ASC 718, provided the market condition within the TSR Shares, the Company measured the grant date fair value using a Monte Carlo valuation model. The fair value of the TSR Shares ($47.37 per share) is multiplied by the target number (100%) of TSR Shares granted to determine total stock‑based compensation expense. Total stock‑based compensation expense of the TSR Shares is amortized on a straight‑line basis over the requisite service period, or three years. Stock‑based compensation expense for the TSR Shares is recognized provided the requisite service period is rendered, regardless of when, if ever, the TSR market condition is satisfied. The Company will reverse previously recognized stock‑based compensation expense attributable to the TSR Shares only if the requisite service period is not met. A summary of the status of the Company’s non‑vested Performance Shares at maximum (200%) attainment for the fiscal year ended June 30, 2019, is presented below:
|  |  |  | Weighted-
|  |  |  | Average
|  | Number of |  | Grant Date
|  | Shares |  | Fair Value
Outstanding at July 1, 2018 |  | 184,664 |  | $ | 61.75
Granted |  | 59,820 |  | $ | 62.77
Vested |  | (21,953) |  | $ | 38.12
Forfeited |  | (7,716) |  | $ | 76.01
Non-attainment |  | (59,793) |  | $ | 52.48
Outstanding at June 30, 2019 |  | 155,022 |  | $ | 68.35
As of June 30, 2019, total unrecognized stock‑based compensation expense related to Performance Shares was approximately $1.6 million, which is expected to be recognized over the average remaining vesting period of 1.9 years. Restricted Stock Officers, non‑executive directors and certain employees may be granted shares of restricted stock that vest on continued service alone (“Restricted Stock”). During fiscal 2019, officers and certain employees were granted 32,840 shares of Restricted Stock. Restricted Stock granted to officers and certain employees vest over three years beginning after a two‑year holding period from the date of grant with one‑third of the shares vesting in years three, four and five, respectively. Also, our non‑executive directors were granted 10,620 shares of Restricted Stock during fiscal year 2019. The non‑executive directors’ shares of Restricted Stock vest 50% immediately and 50% one year after the date of grant. The Company measures the fair value of the Restricted Stock based upon the market price of our common stock as of the date of grant. Restricted Stock is amortized over the applicable vesting period using the straight‑line method. Unvested shares of Restricted Stock are subject to forfeiture upon termination of employment or service with the Company. A summary of the status of the Company’s non‑vested Restricted Stock for the fiscal year ended June 30, 2019, is presented below:
|  |  |  | Weighted-
|  |  |  | Average
|  | Number of |  | Grant Date
|  | Shares |  | Fair Value
Outstanding at July 1, 2018 |  | 144,783 |  | $ | 72.94
Granted |  | 43,460 |  | $ | 77.96
Vested |  | (39,297) |  | $ | 62.32
Forfeited |  | (5,977) |  | $ | 78.95
Outstanding at June 30, 2019 |  | 142,969 |  | $ | 77.13
As of June 30, 2019, total unrecognized stock‑based compensation expense related to Restricted Stock was approximately $4.7 million, which is expected to be recognized over the weighted‑average vesting period of 3.0 years.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration